Share story
AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net. Insilico also said it nominated 11 preclinical candidates in the first 10 months of 2026, bringing its cumulative total since 2021 to 35. Its interim report recorded 8 clinical milestones across internal and partnered pipelines as of mid-August. Rentosertib remains a drug candidate undergoing clinical testing.
Sources
News-Medical.Net
Published by Tech & Business, a media brand covering technology and business. This story was sourced from News-Medical.Net and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Infrastructure Science
Infrastructure Science

Quilty Space projects shortfall of about 150 launches through 2030

The world outside China faces a shortfall of about 150 rocket launches through 2030 against demand from satellite operators and civil space agencies, analytics firm Quilty Space estimates in a new report.

Ars Technica
AI
AI

TBC launches Mischief video model through fal.ai

The Biological Computing Co. is launching Mischief, an image-to-video model based on Wan 2.2, through fal.ai on October 30. Access is free through November 2, with an announced price of $0.02 per second of generated video.

Unite.AI
Products AI
Products AI

Salesforce agrees to acquire military logistics developer Rune

Salesforce signed a definitive agreement to acquire Rune Technologies, a developer of military logistics and sustainment software and hardware, Axios reported. Rune raised ~$30M to build AI military logistics software.

Techmeme